Skeletal manifestations of systemic autoimmune diseases

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 17, Issue 6, 2010, Pages 540-545

  Kamen, Diane L ^a   Alele, Jimmy D ^b  

^a Department of Medicine   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

autoimmunity; lupus; osteoporosis; rheumatoid arthritis; vitamin D

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; DENOSUMAB; PARATHYROID HORMONE[1-34]; PREDNISONE;

AUTOIMMUNITY; BONE DISEASE; BONE NECROSIS; CORTICOSTEROID INDUCED OSTEOPOROSIS; DISEASE ASSOCIATION; HUMAN; OSTEOPOROSIS; PATHOGENESIS; PATIENT MONITORING; POSTMENOPAUSE OSTEOPOROSIS; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; VITAMIN D DEFICIENCY;

AUTOIMMUNE DISEASES; BONE AND BONES; BONE DISEASES; HUMANS; INFLAMMATION; OSTEONECROSIS; OSTEOPOROTIC FRACTURES; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 78649328460     PISSN: 1752296X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MED.0b013e328340533d     Document Type: Review

References (58)

1. Michaud K, Wolfe F. Comorbidities in rheumatoid arthritis. Best Pract Res Clin Rheumatol 2007; 21:885-906.
2. Van Staa TP, Geusens P, Bijlsma JW, et al. Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis. Arthritis Rheum 2006; 54:3104-3112. (Pubitemid 44622079)
3. Haugeberg G, Uhlig T, Falch JA, et al. Bone mineral density and frequency of osteoporosis in female patients with rheumatoid arthritis: results from 394 patients in the Oslo County Rheumatoid Arthritis register. Arthritis Rheum 2000; 43:522-530. (Pubitemid 30394942)
4. Alenfeld FE, Diessel E, Brezger M, et al. Detailed analyses of periarticular osteoporosis in rheumatoid arthritis. Osteoporos Int 2000; 11:400-407.
5. Orstavik RE, Haugeberg G, Uhlig T, et al. Self reported nonvertebral fractures in rheumatoid arthritis and population based controls: incidence and relation-ship with bone mineral density and clinical variables. Ann Rheum Dis 2004; 63:177-182.
6. Huusko TM, Korpela M, Karppi P, et al. Threefold increased risk of hip fractures with rheumatoid arthritis in Central Finland. Ann Rheum Dis 2001; 60:521-522.
7. Kim SY, Schneeweiss S, Liu J, et al. Risk of osteoporotic fracture in a large population-based cohort of patients with rheumatoid arthritis. Arthritis Res Ther 2010; 12:R154.
8. Orstavik RE, Haugeberg G, Mowinckel P, et al. Vertebral deformities in rheumatoid arthritis: a comparison with population-based controls. Arch Intern Med 2004; 164:420-425.
9. Kroot EJ, Nieuwenhuizen MG, de Waal Malefijt MC, et al. Change in bone mineral density in patients with rheumatoid arthritis during the first decade of the disease. Arthritis Rheum 2001; 44:1254-1260.
10. Lane NE.An update on glucocorticoid-induced osteoporosis. Rheum Dis Clin North Am 2001; 27:235-253.
11. Sinigaglia L, Nervetti A, Mela Q, et al. A multicenter cross sectional study on bone mineral density in rheumatoid arthritis. Italian Study Group on Bone Mass in Rheumatoid Arthritis. J Rheumatol 2000; 27:2582-2589.
12. Haugeberg G, Orstavik RE, Uhlig T, et al. Clinical decision rules in rheumatoid arthritis: dotheyidentifypatients at high riskforosteoporosis?Testing clinical criteria in a population based cohort of patients with rheumatoid arthritis recruited from the Oslo Rheumatoid Arthritis Register. Ann Rheum Dis 2002; 61:1085-1089.
13. Lange U, Teichmann J, Muller-Ladner U, et al. Increase in bone mineral density of patients with rheumatoid arthritis treated with anti-TNF-alpha antibody: a prospective open-label pilot study. Rheumatology (Oxford) 2005; 44:1546-1548.
14. Kanis JA, McCloskey EV, Johansson H, et al. Developmentand useofFRAX in osteoporosis. Osteoporos Int 2010; 21 (Suppl 2):S407-S413.
15. Almehed K, Forsblad d'Elia H, Kvist G, et al. Prevalence and riskfactors of osteoporosis in female SLE patients-extended report. Rheumatology (Oxford) 2007; 46:1185-1190.
16. Mendoza-Pinto C, Garcia-Carrasco M, Sandoval-Cruz H, et al. Risk factors of vertebral fractures in women with systemic lupus erythematosus. Clin Rheu-matol 2009; 28:579-585.
17. Becker A, Fischer R, Scherbaum WA, et al. Osteoporosis screening in systemic lupuserythematosus: impactofdiseasedurationand organ damage. Lupus 2001; 10:809-814.
18. Schmajuk G, Yelin E, Chakravarty E, et al. Osteoporosis screening, preven-tion, and treatment in systemic lupus erythematosus: application of the systemic lupus erythematosus quality indicators. Arthritis Care Res (Hobo-ken) 2010; 62:993-1001.
19. Gladman DD, Chaudhry-Ahluwalia V, Ibanez D, et al. Outcomes of sympto-matic osteonecrosis in 95 patients with systemic lupus erythematosus. J Rheumatol 2001; 28:2226-2229. (Pubitemid 32947867)
20. Sayarlioglu M, Yuzbasioglu N, Inanc M, et al. Riskfactors for avascular bone necrosis in patients with systemic lupus erythematosus. Rheumatol Int 2010. [Epub ahead of print]
21. Aranow C, Zelicof S, Leslie D, et al. Clinically occultavascular necrosis of the hip in systemic lupus erythematosus. J Rheumatol 1997; 24:2318-2322.
22. Mok MY, Farewell VT, Isenberg DA. Risk factors for avascular necrosis of bone in patients with systemic lupus erythematosus: is there a role for antiphospholipid antibodies? Ann Rheum Dis 2000; 59:462-467.
23. Chang CC, Greenspan A, Gershwin ME. Osteonecrosis: current perspec-tives on pathogenesis and treatment. Semin Arthritis Rheum 1993; 23:47-69.
24. Kamen DL, Aranow C. The link between vitamin D deficiency and systemic lupus erythematosus. Curr Rheumatol Rep 2008; 10:273-280.
25. Heaney RP. Vitamin D in health and disease. Clin J Am Soc Nephrol 2008; 3:1535-1541.
26. Aloia JF, Chen DG, Yeh JK, et al. Serum vitamin D metabolites and intestinal calciumabsorption efficiency in women. Am J Clin Nutr 2010. [Epub ahead of print]
27. Bischoff-Ferrari HA, Kiel DP, Dawson-Hughes B, et al. Dietary calcium and serum 25-hydroxyvitamin D status in relation to BMD among U.S. adults. J Bone Miner Res 2009; 24:935-942.
28. Brown SE. Vitamin D and fracture reduction: an evaluation of the existing research. Altern Med Rev 2008; 13:21-33.
29. Stechschulte SA, Kirsner RS, Federman DG. Vitamin D: bone and beyond, rationale and recommendations for supplementation. Am J Med 2009; 122:793-802.
30. Bischoff-Ferrari HA, Dietrich T, Orav EJ, et al. Higher 25-hydroxyvitamin D concentrations are associated with better lower-extremity function in both active and inactive persons aged > or =60 y. Am J Clin Nutr 2004; 80:752-758.
31. Kamen DL, Tangpricha V. Vitamin D and molecular actions on the immune system: modulation of innate and autoimmunity. J Mol Med 2010; 88:441-450.
32. Hollis BW. Circulating 25-hydroxyvitamin D levels indicative of vitamin d sufficiency: implications for establishing a new effective dietary intake re-commendation for vitamin D. J Nutr 2005; 135:317-322.
33. Jackson RD, LaCroix AZ, Gass M, et al. Calcium plus vitamin D supplementa-tion and the risk of fractures. N Engl J Med 2006; 354:669-683. (Pubitemid 43247138)
34. Glerup H, Mikkelsen K, Poulsen L, et al. Commonly recommended daily intake of vitamin D is notsufficient if sunlight exposure is limited.J Intern Med 2000; 247:260-268.
35. McLean RR. Proinflammatory cytokines and osteoporosis. Curr Osteoporos Rep 2009; 7:134-139.
36. Barnabe C, Hanley DA. Effect of tumor necrosis factor alpha inhibition on bone density and turnover markers in patients with rheumatoid arthritis and spondyloarthropathy. Semin Arthritis Rheum 2009; 39:116-122.
37. Schett G, Saag KG, Bijlsma JW. From bone biology toclinical outcome: state of the art and future perspectives. Ann Rheum Dis 2010; 69:1415-1419.
38. Pacifici R. T cells: critical bone regulators in health and disease. Bone 2010; 47:461-471.
39. Martin TJ, Seeman E. Bone remodelling: its local regulation and the emer-genceofbonefragility. Best Pract Res Clin Endocrinol Metab 2008; 22:701-722.
40. Teichmann J, Lange U, Stracke H, et al. Bone metabolism and bone mineral density of systemic lupus erythematosus at the time of diagnosis. Rheumatol Int 1999; 18:137-140.
41. Seeman E. Reduced bone formation and increased bone resorption: rational targets for the treatment of osteoporosis. Osteoporos Int 2003; 14 (Suppl 3): S2-S8.
42. Korczowska I, Olewicz-Gawlik A, Hrycaj P, et al. The effect of long-term glucocorticoids on bone metabolism in systemic lupus erythematosus patients: the prevalence of its anti-inflammatory action upon bone resorption. Yale J Biol Med 2003; 76:45-54.
43. Panopalis P, Yazdany J. Bone health in systemic lupus erythematosus. Curr Rheumatol Rep 2009; 11:177-184.
44. Garcia-Carrasco M, Mendoza-Pinto C, Escarcega RO, et al. Osteoporosis in patients with systemic lupus erythematosus. Isr Med Assoc J 2009; 11:486-491.
45. Weinstein RS. Glucocorticoids, osteocytes, and skelet al fragility: the role of bonevascularity. Bone 2010; 46:564-570.
46. National Osteoporosis Foundation. Clinician's guide to prevention and treat-ment ofosteoporosis. Washington, DC: National Osteoporosis Foundation; 2008. pp. 1-36.
47. American College of Rheumatology Ad Hoc Committee on Glucocorticoid- Induced Osteoporosis. Recommendationsforthe prevention andtreatment of glucocorticoid-induced osteoporosis: 2001 update. Arthritis Rheum 2001; 44:1496-1503.
48. Yazdany J, Panopalis P, Gillis JZ, et al. A quality indicator set for systemic lupus erythematosus. Arthritis Rheum 2009; 61:370-377.
49. Chrischilles EA, Dasbach EJ, Rubenstein LM, et al. The effect of alendronate on fracture-related healthcare utilization and costs: the fracture intervention trial. Osteoporos Int 2001; 12:654-660.
50. Harris ST, Watts NB, Li Z, et al. Two-year efficacy and tolerability of risedronate once a week for the treatment of women with postmenopausal osteoporosis. Curr Med Res Opin 2004; 20:757-764.
51. Johnell O, Jonsson B, Jonsson L, et al. Cost effectiveness of alendronate (fosamax) for the treatment of osteoporosis and prevention of fractures. Pharmacoeconomics 2003; 21:305-314.
52. Watts NB. Bisphosphonate treatment of osteoporosis. Clin Geriatr Med 2003; 19:395-414.
53. Bellantonio S, Fortinsky R, Prestwood K. How well are community-living women treated for osteoporosis after hip fracture? J Am Geriatr Soc 2001; 49:1197-1204.
54. Castel H, Bonneh DY, Sherf M, et al. Awareness of osteoporosis and compliance with management guidelines in patients with newly diagnosed low-impact fractures. Osteoporos Int 2001; 12:559-564.
55. Cuddihy MT, Gabriel SE, Crowson CS, et al. Osteoporosis intervention following distal forearm fractures: a missed opportunity? Arch Intern Med 2002; 162:421-426.
56. Torgerson DJ, Dolan P. Prescribing by general practitioners after an osteo-porotic fracture. Ann Rheum Dis 1998; 57:378-379.
57. Ferrari-Lacraz S, Ferrari S. Do RANKL inhibitors (denosumab) affect inflam-mation and immunity? Osteoporos Int 2010. [Epub ahead of print]
58. Engvall IL, Svensson B, Tengstrand B, et al. Impact of low-dose prednisolone on bone synthesis and resorption in early rheumatoid arthritis: experiences from a two-year randomized study. Arthritis Res Ther 2008; 10:R128.